Athena targets ANVISA Approval in 2018

August 2017:

Athena DDS, a technology driven company specialized in Oral Solid Dosage forms, submits levocetirizine 5 mg ODT in Brazil.

'*We are proud to announce our first submission in Brazil with Levocetirizine Oro-Dispersible Tablet. It demonstrates our ability to work successfully in the developed markets; thereby extending our footprint and opening opportunities*.' enunciates Alexandre Williams, Managing director of Athena DDS.

Levoceterizine belongs to the year round (perennial) allergies and children at least 6 months old . This orodispersible form of Levoceterizine has been developed allowing dispersion in less than 20 seconds and can be taken with or without water, thus facilitating administration and patient comfort.

Athena aims to submit 3 to 4 dossiers in the span of 12 months in Brazil adding up to Anvisa approval.

For more information, please contact:

Email: contact@ddsathena.com

About Athena DDS:

Athena with its EU GMP approved facility and state of art R&D Centre is focused on the innovative and value added products in mature and emerging markets and is engaged in Licensing and Development model for Specialty Pharma, Multinationals and other established companies. Athena provides comprehensive product lifecycle management solutions for Oral Solids based on its proprietary technology platforms. Athena has already developed many innovative products CTD format viz., Domperidone ODT, Fenofibrate Capsule, Levocetirizine ODT, Meloxicam ODT, Metformin SR Tablets, Ondansetron ODT, Secnidazole High Dose Sachet as one shot treatment, Racecadotril Sachets, Tramadol Paracetamol ODT & Tablet, Voglibose ODT and Zolpidem ODT & SL ODT. These products are already marketed by leading companies across geographies or are under registration.

For further information, please visit www.athenadds.com